Qlaris Bio has reported positive topline outcomes from two randomised Phase II US trials, Osprey and Apteryx, of QLS 111 in individuals with primary open-angle glaucoma (POAG) and ocular hypertension ...
QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...
Qlaris Bio今日宣布两项临床2期试验Osprey与Apteryx的初步积极结果。这两项试验评估了QLS‑111在原发性开角型青光眼（POAG）和眼内高压（OHT）患者中的疗效。分析显示，两项试验均成功达成了所有的主要和次要终点。
Touting its novel approach for treating glaucoma, Qlaris Bio Inc. reported promising top-line data from two phase II studies testing QLS-111 in patients with primary open-angle glaucoma and ocular ...
QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass., February 05, 2025--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback